All timings shown are UK BST
Nigel R Quine
Founder of Cuts Ice Limited.
Co-Founder of Flavour Core Limited.
Co-Founder of IBVTA (Independent British Vape Trade Association).
Co-Founder of IEVA (Independent European Vape Alliance).
10 years working in the vape industry, developing standards and a sensible regulatory framework for the sector.
Pioneering the development of ‘vape grade’ products and the safety of flavours in ENDS.
Investor in the independent vape channel, promoting specialist retail as the most effective provider of smoking cessation services which keep smokers off harmful combustible products.
Tim Phillips is managing director of ECigIntelligence, the leading source of independent data for the e-cigarette and vaping sector globally, providing unbiased information to numerous leading international companies together with government regulators such as the FDA and the UK government. He is also managing director of a sister publication, CBD-Intel, which is a business intelligence service providing professional, independent market analysis and regulatory tracking for the growing cannabidiol sectors worldwide.
He is a U.K.-qualified attorney, having worked at the European Commission, Herbert Smith, BSkyB, AOL Europe, and as director of public affairs at Betfair as it went through its £1.5bn IPO in 2010. He was also a partner in a New York venture capital-funded startup in the diamond sector. Phillips qualified as a lawyer at the College of Law, London, and holds an MA in Geology from Oxford University.
Ian is an independent consultant with expertise in regulatory and scientific aspects of nicotine and tobacco products. Ian most recently worked for JUUL Labs as Senior Director of Clinical and Regulatory Affairs EMEA, and previously he was Director of Tobacco Research at Celerion, a provider of clinical research capabilities and expertise to the tobacco and e-cigarette industry. Prior to that, Ian was Principal Scientist and Head of Clinical Research at British American Tobacco's central research and development centre in Southampton, U.K. He specializes in the biological and psychological effects of nicotine, clinical and pre-clinical studies to assess the biological effects of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation. Prior to working in the industry, Ian pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor in Biology at McMaster University in Hamilton, Canada. Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers and book chapters which have generated over 2,400 citations.
Rob de Lange chairs Acvoda, the Dutch non-profit organisation which supports Harm Reduction alternatives for consumers, since 2018. Acvoda strives to inform consumers on the risks and benefits of Harm Reduction alternatives to smoking, based on unbiased , peer reviewed studies and scientific research. Mr. de Lange holds the view that only truth based factual information can withstand scrutiny and form a formidable defence against inappropriate regulations and non Harm Reduction based Tobacco regulating ideologies.
As Acvoda’s chair, he holds meetings with consumers, scientists, researchers and policy-makers and acts as a liaison for the Dutch e-cigarette trade organisation, as well as writing various media articles on Harm Reduction. With various certifications in IT-security, Mr. de Lange is well equipped to discern facts from fiction.
David has been working in the tobacco industry as a pre-clinical scientist for 17 years. His work has primarily been focused on the development of in vitro assays for the assessment of cigarette smoke using aerosol exposure systems to more appropriately mimic human inhalation routes of exposure. His experiences cover in vitro genotoxicological, 21st century toxicology, mechanistic screening approaches and 3D physiological models of disease processes. More recently he has adapted his experiences and applied them to the e-cigarette and tobacco heating product environment and helped establish best practices for product assessment of these new categories. David has been the pioneer in advancing in vitro whole aerosol exposure systems, their application and development, creating some innovative and tailored solutions in the in vitro space. David sits on various industry working groups (CORESTA and IIVS) aimed at the standardisation of in vitro assessment approaches which becomes especially important in the light of increased regulation. David is extensively published with more than 40 peer-reviewed publications to name.
Over 30 years’ industry experience both in research & development, regulatory preclinical work & toxicological risk assessment. Director of preclinical toxicology & pharmacology at a CRO for 13 years. Senior Toxicologist/Toxicology Manager at several FMCG companies under the Product Stewardship department, supporting the next Generation Products by advising the company on the Quantitative Risk Assessment procedure under current regulations, the testing strategy for innovative products to ensure their safe commercialization, liaising with external advisors, engaging with regulators & communicating & presenting projects/strategies to internal stakeholders.
Thorough understanding & knowledge of the regulatory pre-requisites for preclinical testing, having put together many preclinical study packages for a large diversity of pharmaceutical compounds with diverse routes of administration & applications (inflammation, pulmonary, gastrointestinal, CNS, etc), including biotechnology-derived products & advanced therapies such as cellular therapy & genetic therapy products, as well as consumer products (oral & inhalation). Carried out toxicological risk-assessment & exposure evaluations for numerous consumer products, including specific assessments of food additives, flavourings & chemicals according to ECHA REACH Technical Guidance. Acted as Expert Advisor to the EC on the 7th Framework Program (FP7), as well as presently under the Eurostars (EUREKA) programme.
John has a strong background and reputation in the European e-cigarette industry having held senior executive positions in some of the US and Europe’s biggest companies. He advises many leading industry analysts, financial institutions and media organisations looking at the vaping and CBD sectors. John is also one of the founders of the UKVIA , the UK’s largest vaping Industry association and has advised the UK governments All Party Parliamentary Group on Vaping as well as giving evidence before the UK Science & Technology Committee investigation into the Vaping industry and the Australian Parliaments review on vaping. John is a regular guest speaker at many of the worlds leading conventions. John regularly appears on national and international television stations and print media to discuss vaping related matters.
Clive Bates has had a diverse career in the public, private and not-for-profit sectors. He started out with the IT company, IBM, then switched career to work in the environment movement. From 1997-2003 he was Director of Action on Smoking and Health (UK), campaigning to reduce the harms caused by tobacco. In 2003 he joined Prime Minister Blair’s Strategy Unit as a civil servant and worked in senior roles in the public sector and for the United Nations in Sudan. He is now Director of Counterfactual, a consulting and advocacy practice focussed on a pragmatic approach to sustainability and public health.
Ao Weinuo is the Secretary-General of the Electronic Cigarette Industry Committee of the China Electronic Chamber of Commerce; he is also one of the main founders of ECCC. ECCC is the only influential & represent the E-Cigarette industry association in China. ECCC has established since January 2017, Ao Weinuo as the key person to draft the “E-Cigarette Standards” into T/CECC 1-2017 & the T/CECC 2-2017 of the "Specification of E-cigarette Liquid " in which ECCC has formally released this implementation on the 20th December 2017. In the past 4 years, Ao Weinuo has often conducted active dialogue & communication with government departments such as State Tobacco Monopoly Administration, the Ministry of Justice, Ministry of Commerce, the China Customs. He has accepted interviews with major media such as CCTV & People’s Daily. In addition, Mr. Ao is the most important planner for the International E-cigarette Industry Summit Forum which held in Shen Zhen every year, giving much time & efforts on promoting the E-cigarette industry in which prospering standard development & maintaining interests among the industry. Ao Weinuo has a senior background in electronics industry for 15 years, once served as Shen Zhen Baoan SEG Electronic Company General Manager, with a wealth of experience in electronic market management & sales of electronic components, mobile phones, digital products, e-cigarettes.
Dustin Dahlmann from Hamburg, Germany is the president of the Independent European Vape Alliance (IEVA), the German vaping industry association BfTG (Bündnis für Tabakfreien Genuss e.V.) and owner of the successful e-cigarette wholesale InnoCigs. He fights for an autonomous regulation of vaping products as a means to harm reduction independent from tobacco industries throughout Europe.
An experienced legal, regulatory & compliance department leader, Patricia I. Kovacevic’s career comprises leading senior legal & regulatory positions with tobacco & cannabis corporations, including Philip Morris International & Lorillard, as well as partner roles with premier global law firms. Her expertise includes senior management roles & leading multinational, cross-disciplinary teams, with focus on corporate law, FDA & EU regulatory, compliance, M&A, US & global food, drug, nicotine & consumer goods regulation, cannabis/CBD regulation, external affairs & the legal framework applicable to marketing, media communications, investigations, FCPA, trade sanctions, privacy, intellectual property, product development & launch. She also led cross-disciplinary teams engaged in scientific research efforts. Kovacevic served on various trade association bodies & conference advisory boards. She authored several articles on nicotine regulation, co-authored an academic treatise, “The Regulation of E-Cigarettes” & is often invited as a keynote speaker or panelist before global conferences & government agencies public hearings. Kovacevic is an attorney admitted to practice in New York, before the U.S. Tax Court, before the U.S. Court of International Trade & before the Supreme Court of the United States. She holds a Juris Doctor (doctor of law) degree from Columbia Law School in New York & completed the Harvard Business School “Corporate Leader” executive education program.
Christopher Russell Ph.D. is the Director of Russell Burnett Research and Consultancy Limited
(RBRC), a contract research organization (CRO) that specializes in the design and conduct of perception and behavioral studies of tobacco and nicotine products. Quantitative and qualitative studies are designed to obtain information about individuals’ use and perceptions of tobacco and nicotine products; understanding of information presented in a product’s label, labelling, and advertising; and intentions to stop, start, and continue using tobacco and nicotine products. The results of these studies help to inform regulatory assessments of the potential impact of new tobacco and nicotine products on future use behavior among tobacco users and nonusers, and so may be submitted as part of premarket tobacco product applications (PMTAs), modified risk tobacco product applications (MRTPAs), or other applicable regulatory submissions.
Sandra’s professional expertise is in toxicology (Eurotox Registered Toxicologist with PhD and two MSc’s). Before she spent years supporting the safety of vaping products as a toxicologist, she worked in several areas relevant to e-cigarettes: household consumer products, medical devices and traditional tobacco products. In her latest current role in regulatory affairs, Sandra’s interest extends to the broader portfolio of products that can play a role in Tobacco Harm Reduction.
Stéphane Colard holds a PhD in Science, a Master in Electronic, and an MBA specialised in Corporate and Social Responsibility. During his professional career, he has managed testing laboratories and scientific research programmes relative to tobacco and electronic cigarette products, addressing a wide range of topics from leaf research to aerosol science. He has participated as an expert and chairman on ISO committees. He is currently Secretary General of CORESTA, a non-profit organisation promoting international cooperation in scientific research.
Jonathan Ng is the Global Head of External Affairs for RELX, and has over 11 years of experience in the tobacco and e-cigarette industries and in various government departments. Prior to joining RELX in October 2019, Mr Ng worked as the Head of Regulatory Affairs and International Trade at HM Sampoerna, the Indonesian affiliate of Philip Morris International, from 2018 to 2019. From 2014 to 2018, Mr Ng held various positions at Philip Morris International in Singapore and Hong Kong, covering innovation strategy, commercialization of reduced-risk products, portfolio strategy and management, and regulatory affairs. Before joining Philip Morris International, Mr Ng was an officer of the Administrative Service of the Singapore Government. He worked as the Senior Assistant Director of the Public Service Division at the Prime Minister’s Office in Singapore and as a Country Officer on the Indonesia desk of the Ministry of Foreign Affairs of Singapore. Mr Ng holds a Master in Finance degree from Princeton University and a Bachelor’s degree in Economics from the London School of Economics and Political Science.
Gabe Barnard is Head of New Business at The Centre for Substance Use Research (CSUR). CSUR is a multi-disciplinary research group conducting behavioural science studies assisting companies seeking approval for their ENDS products under PMTA, MRTP, and TPD requirements.
Gabe’s responsibilities as Head of New Business at the Centre primarily involve identifying possible new areas of research. In doing so Gabe aims to identify future questions relevant to ENDS regulators, manufacturers, retailers, and customers and to identify how innovative behavioural research studies can assist these groups. As Head of New Business an important part of Gabe’s role has to do with establishing links with industry.
Gabe has been working in close collaboration with the CSURES research team jointly designing the CARE research study (Comparative Assessment of Real-world ENDS). This study is designed to assess the rates with which different ENDS products may be meeting the needs of diverse groups of adult smokers seeking to quit or reduce their use of combustible tobacco products. The results of the CARE study should assist companies seeking marketing authorisation for their ENDS products.
Mark Oates is the Director of We Vape and the Snus Users Association. Which are both consumer groups standing up for the right for individuals to use safer nicotine products. He advocates for evidence-based harm reduction in a range of areas from tobacco to drug policy, a subject he has written on for the Institute of Economic Affairs & the Adam Smith Institute where he is a Fellow. He also provided consumer evidence in the 2018 ECJ case to overturn the ban of snus across the European Union and worked on the successful 2018 campaign to legalise medical cannabis in the UK.
Sally has over 25 years of experience in gas chromatography supplementing that in the last 10 years with other chromatography/mass spectrometric techniques. She also has more than 10 years experience in the field of ENDS (Electronic Nicotine Delivery Systems) and E&L (Extractables and Leachables). She is highly experienced in method development/validation, defining and designing study plans and final data review.
Sally has a BSc in Chemistry. She is also a member of CORESTA Subgroup & Taskforce and a BSI Committee member.
Shane Smith is the Managing Director of ExtLe Solutions Limited, a company based in Cambridge in the UK. He has over 35 years of experience in industrial analytical chemistry, with three quarters of that time spent in the pharmaceutical sector. As well as being an expert on extractables and leachables (E&L), he is a specialist in trace analysis and the separation sciences.
From 2004, he worked for GlaxoSmithKline’s world class E&L team at Stevenage in the UK, managing E&L projects for global cross-site project teams. He was ultimately responsibility for the E&L content of successful filings submitted to Regulatory Agencies across the world including North America, Europe, and other territories.
Shane left GlaxoSmithKline in early 2016 to pursue a career as an Independent Consultant and set up ExtLe Solutions to provide specialist E&L consultancy services.
With over 40 years’ combined experience dealing with E&Ls in an ever increasingly complex regulatory environment within the pharmaceutical industry, Shane and the team at ExtLe Solutions are able to apply best practise to ENDS and e-liquid products, resulting in robust, scientifically sound E&L strategies for their clients’ products.
Dr Nveed Chaudhary is Chief Regulatory Officer at Broughton Nicotine Services. He has over 15 years of experience in the Next Generation nicotine products industry. He has a Double Hons degree in Pharmacology & Physiology, University College London & a PhD in Respiratory Molecular Medicine, University of Southampton. Worked for the pharmaceutical industry & at Boehringer Ingelheim & was the co-inventor of a novel drug for the treatment of idiopathic pulmonary fibrosis, nintedanib esylate, which received regulatory approval in 2014/15. Since 2006, he has worked at three of the largest tobacco companies in the World, focused on the assessment & subsequent regulatory filing of NGPs, including e-cigarettes, heated tobacco products & modern oral nicotine products. His experience at BAT & Philip Morris Int’l included leading multi-disciplinary, globally based teams on both pre-clinical & clinical assessment of NGPs. At Philip Morris Int’l he was Director of Strategic Communications, with a focus on Tobacco Harm Reduction (THR). In this role, as well as creating narratives around THR for regulatory & key opinion leader engagement, he also had a critical role in creating the narratives for the Premarket Tobacco Product Applications (PMTA) & Modified Risk Tobacco Product (MRTP) applications for IQOS. Most recently, Nveed directed the PMTA programme at Imperial Brands ensuring the timely submission of PMTA applications to support Imperial Brand’s range of deemed products in the USA
-04.jpg?ext=.jpg){kind=logo}
Richard joined bibra toxicology advice & consulting in January 2003 and has over 18 years' experience in desk-based toxicology. He has a MSc (distinction) in Applied Toxicology from Surrey University and is a BTS/RSB and European Registered Toxicologist (ERT). He is also a member of the Royal Society of Biology (MRSB), the British Toxicology Society (BTS) and the Chemical Hazards Communication Society (CHCS).
His special interests include the pragmatic application of risk assessment methodology to mammalian toxicity data sets, in order to derive robust conclusions on toxicological acceptability of exposures and on health risks to exposed populations. He has worked for clients from various sectors, including food and beverage, food contact materials, consumer goods, agrochemical, biocidal, industrial chemical (primary REACH), pharmaceutical (including human medicines and medical devices), non-tobacco nicotine delivery devices (NTNDD) – notably e-cigarettes (ENDS) in the last few years (e.g. PMTA and TPD2 submissions), and most recently the assessment of cannabinoids (e.g. CBD and THC).
Tryggve Ljung is the Vice President Scientific Affairs at Swedish Match Tryggve holds an MD and PhD from Karolinska Institutet and remains an academic affiliation as an associate professor at Uppsala University. Tryggve has worked as a senior consultant at the Karolinska University Hospital before joining the pharmaceutical industry were he worked as Medical Director for several companies before joining Swedish Match in 2018. Swedish Match Scientific Affairs is part of the company´s cross-functional team responsible for pre-clinical and clinal studies and regulatory applications such as the successful General Snus PMTA and MRTP applications.
